The option that simultaneous inhibition of both CK2 and MEK may exert stronger anti-tumour outcomes has been explored in HNSCC cells by co-administration of CX-4945 and PD-0325901, a selective and non-ATP-competitive MEK inhibitor recently entered in clinical trials, whose anti-tumour efficacy has been shown in many preclinical studies in different human cancers [62, 85, 86, (https://clinicaltrials.gov/ct2/home)]. The gene discussed is MAP2K7; the disease is neoplasm.